4 Results for "

HIPK2-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "HIPK2-IN-2" in MCE Product Catalog:

Cat. No.: HY-189141
Research Areas:  

Endocrinology

HIPK2-IN-2 is an orally active and selective HIPK2 inhibitor with an IC50 of 0.36 μM against HIPK2. HIPK2-IN-2 reduces HIPK2 protein expression levels. HIPK2-IN-2 inhibits the proliferation and migration of renal interstitial fibroblasts, alleviates renal tubular injury and collagen deposition, and suppresses TGF-β/Smad3-mediated profibrotic signaling pathways as well as TNF-α/NF-κB-mediated inflammatory signaling pathways in renal cells. HIPK2-IN-2 is used for the study of chronic kidney disease-associated renal fibrosis .
loading...
    loading...
Cat. No.: HY-E70830
Target:  

DYRK

Research Areas:  

Cancer

Homeodomain interacting protein kinase 2 (HIPK2) is an evolutionary conserved serine/threonine kinase that regulates gene expression by phosphorylation of transcription factors and accessory components of the transcription machinery. HIPK2 is activated in response to DNA-damaging agents or morphogenic signals. HIPK2 Recombinant Human Active Protein Kinase is a recombinant HIPK2 protein that can be used to study HIPK2-related functions .
loading...
    loading...
Cat. No.: HY-RS23297
Research Areas:  

Others

Hipk2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Hipk2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Components

Hipk2 siRNA-1: 5 nmol (HPLC)

Hipk2 siRNA-2: 5 nmol (HPLC)

Hipk2 siRNA-3: 5 nmol (HPLC)

siRNA Negative Control: 5 nmol (HPLC)

FAM-labeled siRNA Negative Control: 5 nmol (HPLC)

GAPDH siRNA Positive Control: 5 nmol (HPLC)

loading...
    loading...
Cat. No.: HY-122670
CAS No.: 1627962-21-3
Research Areas:  

Cancer

VS-II-173 is a pan-Pim kinase inhibitor with IC50 values ​​of 0.07 μM and 0.02 μM for Pim1 and Pim3, respectively, and a residual activity of 46% for Pim2 at 1 μM. VS-II-173 also inhibits kinases such as HIPK2, PRK2, RSK1, DYRK1a and AMPKα1, selectively inhibiting acute myeloid leukemia (AML) cells with significantly lower toxicity to non-malignant cells (EC50 > 30 μM). VS-II-173 weakens the phosphorylation of substrates such as Stat5 (Y694), MDM2 (S166), Bad (S112), and 4E-BP1 (T37/46) by inhibiting Pim kinase-mediated signaling pathways, blocking pro-survival signals in AML cells and inducing apoptosis. VS-II-173 synergistically enhances anti-AML activity when combined with Daunorubicin (HY-13062A). VS-II-173 can be used in AML research, especially for AML with FLT3-ITD mutations and NPM1 mutations .
loading...
    loading...